Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 9/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3343887 | 1.00 | P2RX7 (0.52) | P2RX7RIPK1NFKB1NFKB2RELA | |
| SCHEMBL3830752 | 0.87 | P2RX7 (0.50) | P2RX7RIPK1NFKB1NFKB2RELA | |
| SCHEMBL4349642 | 0.87 | P2RX7 (0.53) | P2RX7RIPK1ALDH1A1 | |
| SCHEMBL26984284 | 0.87 | P2RX7 (0.50) | P2RX7RIPK1NFKB1NFKB2RELA | |
| SCHEMBL3341987 | 0.86 | P2RX7 (0.54) | P2RX7 | |
| SCHEMBL1100850 | 0.86 | P2RX7 (0.54) | P2RX7 | |
| SCHEMBL16400796 | 0.86 | P2RX7 (0.46) | P2RX7MEN1KMT2A | |
| SCHEMBL3347125 | 0.84 | RIPK1 (0.47) | P2RX7RIPK1ALDH1A1 | |
| SCHEMBL3347134 | 0.84 | RIPK1 (0.47) | P2RX7RIPK1ALDH1A1 | |
| SCHEMBL3344885 | 0.84 | KDM4E (0.47) | RIPK1ALDH1A1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108290881-B | Therapeutic compounds and methods of use thereof | 健泰科生物技术公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-2393781-B1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| EP-2393781-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-12-14 | — | — | EP | disclosed |
| CN-102264701-A | Dihydropyridone ureas as P2X7 modulators | — | 2011-11-30 | — | — | CN | disclosed |
| WO-2010072599-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | P2RY1, P2RX1, P2RX3 | P2RX7 5/4885RIPK1 1786/4885NFKB1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.